Timothy Novak, D.B.A., M.S.A., FACHT, dean of Lake Erie College of Osteopathic Medicine (LECOM) School of Health Services Administration (SHSA), announced today licensing approval by the Florida Department of Education’s Committee for Independent Education for LECOM’s four semester, 45 credit hour, fully on-line Master of Science in Medial Cannabinoid Therapeutics (M.S. MCT) Program launching June 4, 2022.
The LECOM M.S. MCT curriculum focuses on the business, compliance, efficacy, and pharmacokinetics of the rapidly expanding, multi-billion-dollar medical cannabis industry in the U.S. and around the world. Graduate students will examine fundamental knowledge areas including economics, vertical business integration models, biosynthetic pathways, therapeutic drug design, government regulations and policies, ethics, public health impacts and safety issues. Rigorous research and analysis will take place throughout the program, culminating with a thesis or capstone project. The primary goal is to formally prepare graduates to apply their findings to real-world decision-making throughout the healthcare industry and more effectively communicate and interface with local, state, and federal governments concerning a broad range of medical cannabis healthcare issues.
“Our goal is providing students the tools and relevant knowledge needed to create highly effective, formally trained healthcare business industry leaders. We will help prepare these talented professionals to understand and solve the many and complex healthcare industry challenges facing our communities, nation and the world today.” Said Dr. Novak.
“LECOM, as the largest medical college in the U.S., is excited to offer this much needed and innovative medical cannabis master’s program to help expand understanding, protect whole person community health, and encourage rigorous research into this fast-growing medical cannabis healthcare sector,” said Silvia M. Ferretti, D.O., Senior Vice President, Provost and Dean of Academic Affairs for LECOM.